GlassScriptPhysician profile
Daniela Gamboa Sejas
NPI 1417141912
$7,675.70
in general payments reported to CMS, 2019-2025
41 companies · $1,886 in 2025
The $1,886 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $746 · 2020: $1,175 · 2021: $528 · 2022: $908 · 2023: $1,248 · 2024: $1,185 · 2025: $1,886.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,209 · Education: $110.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,209.29 |
| Education | $109.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,774.27 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $777.04 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Lilly USA, LLC | $761.63 | 2020-2025 | Jardiance, Mounjaro, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $510.58 | 2019-2025 | Jardiance |
| Amgen INC. | $421.26 | 2024-2025 | Repatha, Repatha, Otezla |
| Glaxosmithkline, LLC. | $363.47 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbvie INC. | $355.02 | 2020-2025 | |
| Merck Sharp & Dohme LLC | $283.09 | 2019-2023 | Belsomra, Steglujan, Steglatro |
| Pfizer INC. | $164.68 | 2019-2025 | |
| Amarin Pharma, INC. | $161.15 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $159.34 | 2024-2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $144.93 | 2019-2024 | Trintellix |
| Currax Pharmaceuticals LLC | $139.80 | 2020-2023 | Nexletol, Contrave, Nexlizet |
| Astellas Pharma US INC | $136.60 | 2021-2025 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $125.40 | 2023-2025 |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $113.78 | 2025 | Ajovy |
| Axsome Therapeutics, INC. | $106.68 | 2025 | Auvelity |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $102.36 | 2019-2024 | Cycloset, Trulance, Xifaxan |
| Allergan, INC. | $93.29 | 2019-2020 | |
| Lundbeck LLC | $92.72 | 2024-2025 | Rexulti, Vyepti |
| Eisai INC. | $88.70 | 2020-2022 | |
| Corcept Therapeutics | $83.42 | 2025 | Korlym |
| Exact Sciences Corporation | $81.16 | 2024-2025 | Cologuard Collection Kit |
| Abbott Laboratories | $79.39 | 2022-2023 | Freestyle Libre 3 |
| Azurity Pharmaceuticals, INC. | $66.12 | 2023 | Adthyza, Horizant |
| Idorsia Pharmaceuticals US INC | $65.42 | 2023-2025 | Quviviq, Quviviq |
| Dexcom, INC. | $57.69 | 2022-2025 | Dexcom G6 Transmitter |
| Alkermes, INC. | $54.23 | 2024-2025 | Vivitrol |
| Endo Pharmaceuticals INC. | $42.31 | 2021 | |
| Ironwood Pharmaceuticals, INC | $40.16 | 2020 | |
| Verity Pharmaceuticals INC. | $33.97 | 2025 | Tlando |
| Janssen Pharmaceuticals, INC | $33.79 | 2019 | |
| Althera Pharmaceuticals LLC | $30.50 | 2021-2022 | |
| Vivus LLC | $23.11 | 2023 | Qsymia |
| Sumitomo Pharma America, INC. | $20.95 | 2024 | Gemtesa |
| Tolmar, INC. | $17.69 | 2025 | Jatenzo |
| Genentech USA, INC. | $17.31 | 2019 | |
| Avvisto Therapeutics, LLC | $14.43 | 2024 | Cycloset |
| Arbor Pharmaceuticals, INC. | $13.44 | 2022 | |
| Nestle Healthcare Nutrition INC. | $13.09 | 2022 | |
| Aytu Biopharma, INC. | $11.73 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniela Gamboa Sejas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.